CA3127569A1 - Method of diagnosis - Google Patents

Method of diagnosis Download PDF

Info

Publication number
CA3127569A1
CA3127569A1 CA3127569A CA3127569A CA3127569A1 CA 3127569 A1 CA3127569 A1 CA 3127569A1 CA 3127569 A CA3127569 A CA 3127569A CA 3127569 A CA3127569 A CA 3127569A CA 3127569 A1 CA3127569 A1 CA 3127569A1
Authority
CA
Canada
Prior art keywords
subject
antibody
adiponectin
polypeptide
pancreatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3127569A
Other languages
English (en)
French (fr)
Inventor
Eithne COSTELLO
William Greenhalf
Lucy OLDFIELD
Christopher HALLORAN
Paula GHANEH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Liverpool
Original Assignee
University of Liverpool
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1902193.0A external-priority patent/GB201902193D0/en
Priority claimed from GBGB1903424.8A external-priority patent/GB201903424D0/en
Application filed by University of Liverpool filed Critical University of Liverpool
Publication of CA3127569A1 publication Critical patent/CA3127569A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/067—Pancreatitis or colitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CA3127569A 2019-02-18 2020-02-17 Method of diagnosis Pending CA3127569A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1902193.0A GB201902193D0 (en) 2019-02-18 2019-02-18 Method of diagnosis
GB1902193.0 2019-02-18
GB1903424.8 2019-03-13
GBGB1903424.8A GB201903424D0 (en) 2019-03-13 2019-03-13 Method of diagnosis
PCT/EP2020/054046 WO2020169511A1 (en) 2019-02-18 2020-02-17 Method of diagnosis

Publications (1)

Publication Number Publication Date
CA3127569A1 true CA3127569A1 (en) 2020-08-27

Family

ID=69591656

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3127569A Pending CA3127569A1 (en) 2019-02-18 2020-02-17 Method of diagnosis

Country Status (7)

Country Link
US (1) US20220091140A1 (https=)
EP (1) EP3903105A1 (https=)
JP (1) JP7660077B2 (https=)
CN (1) CN113454459A (https=)
AU (1) AU2020223826A1 (https=)
CA (1) CA3127569A1 (https=)
WO (1) WO2020169511A1 (https=)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1426764T3 (da) * 2001-08-17 2011-06-27 Fujirebio Kk Fremgangsmåde til diagnosticering eller monitorering af fejl i sukkermetabolisme
EP1590434A4 (en) * 2003-01-17 2006-11-29 Univ New York State Res Found ASSOCIATED ANTIGEN, ANTIBODIES, AND DIAGNOSIS AND TREATMENT METHODS WITH CONCENTRATED CANNULA CANCER
US20060105419A1 (en) * 2004-08-16 2006-05-18 Biosite, Inc. Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
US8632983B2 (en) * 2005-04-15 2014-01-21 Van Andel Research Institute Biomarkers for pancreatic cancer and diagnostic methods
CA2645125A1 (en) * 2006-03-02 2007-09-13 Oncotherapy Science, Inc. Methods for diagnosing pancreatic cancer using reg4 protein
CN102939541B (zh) * 2010-06-15 2015-12-02 弗·哈夫曼-拉罗切有限公司 手术后急性肾损伤的预测和识别
JP2014510516A (ja) * 2011-02-15 2014-05-01 ノヴォ ノルディスク アー／エス 長時間作用性ｉｌ−１受容体アンタゴニスト
GB201103726D0 (en) * 2011-03-04 2011-04-20 Immunovia Ab Method, array and use thereof
JP6189754B2 (ja) * 2011-03-04 2017-08-30 イントレキソン コーポレーション タンパク質を条件的に発現するベクター
US20160231334A1 (en) * 2013-10-28 2016-08-11 The Forsyth Institute Compositions and Methods for Evaluating Metabolic Syndrome and Related Diseases
WO2015112429A1 (en) 2014-01-23 2015-07-30 Newomics Inc Methods and systems for diagnosing diseases
WO2015157557A1 (en) 2014-04-09 2015-10-15 Myriad Rbm, Inc. Methods of diagnosing pancreatic cancer and methods related thereto
BR112017002884A2 (pt) * 2014-08-14 2018-01-30 Memed Diagnostics Ltd ?análise computacional de dados biológicos por meio do uso de variedade e hiperplano?
EP3209804A4 (en) * 2014-10-22 2018-02-28 The George Washington University A Congretionally Chartered Not-For-Profit Corp. Blood biomarkers for appendicitis and diagnostics methods using biomarkers
WO2017019588A1 (en) * 2015-07-28 2017-02-02 The Johns Hopkins University Compositions and methods for detecting pancreatic cancer
GB201522839D0 (en) 2015-12-23 2016-02-03 Randox Lab Ltd And Randox Teoranta Method
US12416636B2 (en) * 2018-05-31 2025-09-16 University Of Florida Research Foundation, Inc. Personalized treatment of pancreatic cancer

Also Published As

Publication number Publication date
US20220091140A1 (en) 2022-03-24
CN113454459A (zh) 2021-09-28
JP2022529073A (ja) 2022-06-16
JP7660077B2 (ja) 2025-04-10
WO2020169511A1 (en) 2020-08-27
AU2020223826A1 (en) 2021-08-05
EP3903105A1 (en) 2021-11-03

Similar Documents

Publication Publication Date Title
Tian et al. The diagnostic value of serum C-reactive protein, procalcitonin, interleukin-6 and lactate dehydrogenase in patients with severe acute pancreatitis
ES2944613T3 (es) proADM y/o histonas como marcadores indicadores de un acontecimiento adverso
JP6774925B2 (ja) 性別に基づく疾病の識別・評価・予防及び治療を含む、肺病の識別・評価・予防及び治療のための方法並びにそのキット
US9933429B2 (en) Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
KR20170130441A (ko) 암 진단용 바이오마커 패널
EP3132266B1 (en) New biomarkers for metastatic breast cancer
JP6983221B2 (ja) 大腸癌の併用検査
Lipshitz et al. Emerging markers of cancer cachexia and their relationship to sarcopenia
EP3931571B1 (en) Protein signature for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof
EP3835789A1 (en) Biomarker panel for diagnosing colorectal cancer
JP2012050369A (ja) ＩｇＧ４関連疾患診断用マーカー及びその利用
JP7660077B2 (ja) 診断方法
CN114286942B (zh) 检测癌症的方法
JP7614477B2 (ja) 間質性肺炎のタンパク質診断バイオマーカー
TW201930881A (zh) 大腸直腸腺瘤之檢測及治療方法
ES2825573T3 (es) Medios y métodos para determinar el riesgo de diabetes tipo 1 mediante biomarcadores de proteínas séricas
CN117642630A (zh) 用于非酒精性脂肪肝病的纤维化生物标志物
Zaki et al. Can Noninvasive Tests Substitute Endoscopy for Diagnosis of Colonic Diseases?
Joy et al. Evaluation of some Renal Biomark-ers, Interleukin–4 and Troponin Among Patients with Prostate Cancer Attending Chukwuemeka Odumegwu Ojukwu University Awka. Intern J of Gyne Rese and Women Health Research Article 1 (1): 01-06
EP4137581A1 (en) Protein diagnostic biomarker for severe drug eruption
WO2026049057A1 (ja) リスク値の検出方法、ｉｃａｎｓ発症可能性の予測を補助する方法、医薬およびｉｃａｎｓ発症予測用キット
Michael et al. Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease
HK40058647B (zh) 监定、评估、预防以及治疗肺疾病的方法及试剂盒
Obiageli et al. Evaluation of Some Renal Biomarkers, Interleukin–4 and Troponin Among Patients with Prostate Cancer Attending Chukwuemeka Odumegwu Ojukwu University Awka

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250902

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260331